Stock Market | FinancialContent Business Page
FinancialContent fully hosted finance channel
Foster City United States Zimberelimab Monotherapy Melissal Johnson Dimitry Sa Nuyten Exchange Commission
Source: financialcontent.com
📰 Objective Response Rate News
Page 5 - Objective Response Rate News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Objective Response Rate. Real-time updates on events, politics, business and more.
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in
– Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC –– Objective Response Rate (ORR) Improved in Both Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy –– Re...
Source: pharmiweb.com
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity,...
Source: prnewswire.com
Future Outlook of Advanced Ovarian Cancer Treatment
Comprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.
Advanced Ovarian Cancer Treatment Recent Updates Later Line Maintenance Settings Advanced Ovarian Cancer Antibody Drug Conjugate Soraya Trial
Source: onclive.com
Laboratorios Farmaceuticos Rovi S A : ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE)
Español img_0229_0.jpg ROVI COMMENCES CLINICAL DEVELOPMENT OF A NEW THREE-MONTHLY FORMULATION OF LETROZOLE ... | April 25, 2023
United States United Kingdom European Parliament Drug Administration United States Food Capital Markets Day
Source: marketscreener.com
China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released
/PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted...
Mabwell Taizhou Prnewswire Mabwell Significant New Drugs Development National Key Rd Programmes Urothelial Carcinoma Objective Response Rate
Source: prnewswire.com
BioAtla Reports Fourth Quarter and Full Year 2022 Financial
- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS)...
Source: globenewswire.com
BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
- Cleared dose-limiting toxicity observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma cohort readout in 2H23 - Initiated the potentially... | March 23, 2023
Source: marketscreener.com
Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
15.03.2023 - Company on Track for PROC Phase 3, Pivotal Trial Readout in Mid 2023; Ends Year with Strengthened Cash PositionHOUSTON, March 15, 2023 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company ...
Source: wallstreet-online.de
Galapagos NV: Galapagos announces full year 2022 results and outlook for 2023
Key 2022 and post-period events Dr. Paul Stoffelsi appointed as Chief Executive Officer and Chairman of the Board of DirectorsImplemented new strategic direction to accelerate innovation and time-to-patients:
Source: finanznachrichten.de